Oliver Reuss

Observer, Board of Directors
2024
Glox Therapeutics is developing precision, engineered protein bacteriocins to target drug-resistant pathogenic bacteria.

2021

Member, Board of Directors
2021
Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Currently, Brainomix utilizes its platform technology to expand into new therapeutic indications, including lung fibrosis and cancer. Brainomix is a spin-out from the University of Oxford, UK.

2020

Member, Board of Directors
2020
Perfood develops digital therapeutics powered by proprietary technology for personalized stable-glycemic nutrition. Perfood is building a pipeline of therapeutic solutions, where its core competence of modulating the glucose metabolism and inflammatory processes add disease-specific value. Find out more on www.perfood.de

2019

Member, Board of Directors
2019
Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. The goal is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Find out more on www.dopavision.com

2008 - 2018

2007 - 2008

2006 - 2007

Executive Director / Investment Manager at Boehringer Ingelheim Venture Fund; Board of Directors at Dopavision, Perfood, Brainomix, Glox